bezafibrate has been researched along with Diabetic Retinopathy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ebihara, N; Ouchi, Y; Usui-Ouchi, A | 1 |
| Mori, M; Nagai, T; Nakajima, K; Tomizawa, T | 1 |
2 other study(ies) available for bezafibrate and Diabetic Retinopathy
| Article | Year |
|---|---|
The peroxisome proliferator-activated receptor pan-agonist bezafibrate suppresses microvascular inflammatory responses of retinal endothelial cells and vascular endothelial growth factor production in retinal pigmented epithelial cells.
Topics: Anti-Inflammatory Agents; Bezafibrate; Cells, Cultured; Chemokine CCL2; Diabetic Retinopathy; Endothelial Cells; Humans; Inflammation; NF-kappa B; Peroxisome Proliferator-Activated Receptors; Retina; Retinal Pigment Epithelium; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2017 |
Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients.
Topics: Albuminuria; Apolipoprotein A-I; Apolipoprotein B-100; Apolipoproteins B; Bezafibrate; Blood Pressure; Case-Control Studies; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Humans; Hypercholesterolemia; Hypolipidemic Agents; Insulin; Lipids; Male; Middle Aged; Pravastatin | 2000 |